Abstract : Biphasic insulin aspart NovoMix® 50 is a new premixed insulin preparation that contents 50 % of ultra-short acting insulin analogue aspart and 50 % of protaminated insulin aspart. As compared to NovoMix® 30, NovoMix® 50 results in a better control of postprandial hyperglycaemia thanks to a greater proportion of the ultra-short acting insulin analogue. Another preparation called NovoMix® 70 extends the panel of NovoNordisk, and will be soon commercialised in Belgium. These premixed insulin preparations can be used in one (rather rarely), two (most classically) or three (more and more frequently, i.e. before each of the three main meals) subcutaneous injections per day. They are used in the management of type 2 diabetes, eventually in association with metformin. These insulin preparations are available in Penfill cartridges for NovoPen ®. The launch of premixed insulin preparations, containing different proportions of short-acting and intermediate insulin formulations, offers a greater flexibility to medical doctors and facilitates the selection, according to the moment of the day, of the insulin mixtures that allow the best control of prandial and basal glycaemia, while limiting the risk of hypoglycaemia.